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Background: Mutations in the Pleckstrin homology domain-containing, family G member 5 (PLEKHG5) gene has been
reported in a family harboring an autosomal recessive lower motor neuron disease (LMND). However, the PLEKHG5
mutation has not been described to cause Charcot-Marie-Tooth disease (CMT).
Methods: To identify the causative mutation in an autosomal recessive intermediate CMT (RI-CMT) family with
childhood onset, whole exome sequencing (WES), histopathology, and lower leg MRIs were performed. Expression
and activity of each mutant protein were analyzed.
Results: We identified novel compound heterozygous (p.Thr663Met and p.Gly820Arg) mutations in the PLEKHG5
gene in the present family. The patient revealed clinical manifestations of sensory neuropathy. Fatty replacements
in the distal lower leg muscles were more severe than in the thigh muscles. Although the symptoms and signs of
this patient harboring slow nerve conduction velocities suggested the possibility of demyelinating neuropathy, a
distal sural nerve biopsy was compatible with axonal neuropathy. Immunohistochemical analysis revealed that the
patient has a low level of PLEKHG5 in the distal sural nerve and an in vitro assay suggested that the mutant
proteins have a defect in activating the NF-κB signaling pathway.
Conclusions: This study identifies compound heterozygous PLEKHG5 mutations as the cause of RI-CMT. We suggest
that PLEKHG5 might play a role in the peripheral motor and sensory nervous system. This study expands the
phenotypic spectrum of PLEKHG5 mutations.
Keywords: Charcot-Marie-Tooth disease (CMT), Lower motor neuron disease (LMND), Pleckstrin homology
domain-containing, Family G member 5(PLEKHG5), Exome, NeuropathyBackground
Mutation in Pleckstrin homology domain-containing, family
G member 5 (PLEKHG5) has been reported only in a family
with lower motor neuron disease (LMND) with childhood
onset [1]. LMND, which is a large group of clinically and
genetically heterogeneous disorders, is usually diagnosed
by electrophysiological or histological evidence of muscle
denervation without sensory neuropathy [2,3]. Except for* Correspondence: kwchung@kongju.ac.kr; bochoi@ewha.ac.kr
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reproduction in any medium, provided the orPLEKHG5, many other causative genes have been reported
in LMNDs: SMN1 and DYNC1H1in each autosomal
recessive (AR) and dominant spinal muscular atrophy
(SMA: MIM 253300 and 158600), HSPB1,HSPB8, and
HSPB3in distal hereditary motor neuronopathy type 2
(dHMN2: MIM 608634, 158590 and 613376), GARS,
BSCL2 and REEP1 in dHMN5 (MIM 600794 and 614751),
IGHMBP2 in dHMN6 (MIM 604320), DCTN1 and
SLC5A7 in dHMN7 (MIM 607641 and 158580), ATP7A in
X-linked dHMN and SMA (MIM 300489), and SETX
in dHMN with pyramidal sign (MIM 602433) [2-11].
The affected individuals harboring a PLEKHG5 mutation
presented with severe generalized distal and proximal
muscle weakness and atrophy, but normal sensation;. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Pedigree, sequencing chromatograms and conservation in the FC307 family with compound heterozygous PLEKHG5 mutations.
(A) Pedigree. Open symbols indicate unaffected individuals and the filled symbol indicates the affected individual. Half-filled symbols indicate carriers
possessing one mutant allele. The arrow indicates the proband. Genotypes of both PLEKHG5 mutations are indicated at below each examined
individual. (B) Sequencing chromatograms. Vertical arrows indicate the mutation site. (C) Conservation analysis of amino acid sequences. The analysis
was conducted using MEGA5 version 5.05 software. Both mutation sites were well conserved across species.
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dHMN [12] or generalized SMA [1]. However, there
has been no report of a PLEKHG5 mutation relevant to
Charcot-Marie-Tooth disease (CMT), which is also called
hereditary motor and sensory neuropathy (HMSN).
CMT is a clinically and genetically heterogeneous
disorder of the peripheral motor and sensory nervous
system [13]. CMT has been reported to be associatedwith more than 50 causative genes or loci [14]. Based
on nerve biopsy and neurophysiology, CMT falls into
two main subtypes, a demyelinating form (CMT1), and
an axonal form (CMT2) [15]. An intermediate group
exists with nerve conduction velocities, which overlaps
the two main groups, and is subdivided into dominant
intermediate (DI-CMT) and recessive intermediate CMT
(RI-CMT) by its pattern of inheritance [16]. Intermediate
Table 1 Whole exome sequencing analysis in the affected
individual (III-1)
Items FC307 (III-1)
Total sequencing yields (Gbp) 6.5
% Mappable reads (/total reads) 94.0
% Coverage of target regions (more than 10X) 93.4
Mean read depth of target regions 88.5X
Total observed SNPs 57,356




Functionally significant variantsa 9,136
Functionally significant variants in CMT genes 30
CMT, Charcot-Marie-Tooth disease; SNP, single nucleotide polymorphism.
aNonsynonymous variants include splicing site, frameshift, stop gain, and
stop loss.
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cells [17,18].
PLEKHG5 is predominantly expressed in the periph-
eral nervous system, and the protein contains a DH
(Dbl homology)- PH (Pleckstrin homology) motif, which is
known as the minimal unit for the nucleotide exchange-
promoting function of guanine nucleotide exchange factors
(GEFs) [19]. PLEKHG5 protein has been suggested to have
a role in the activation of the RhoA exchange factor and
NF-κB signaling pathway [20], and it thus appears to be
involved in neuronal cell differentiation. It is suggested that
both loss of function in the NF-κB transduction pathway
and aggregate formation of mutant PLEKHG5 might
contribute to neurotoxicity [1,2].
In this study, we investigated a Korean RI-CMT family
with childhood onset, and identified novel compound
heterozygous mutations of PLEKHG5. To our knowledge,




This study enrolled 248 individuals in 160 unrelated
families with variable types of CMT neuropathy. They were
referred by their primary physicians or neurologists and
selected negative for PMP22 duplication and major CMT
gene mutations during the period 2003–2012. This study
also included 300 healthy controls. Informed consent was
obtained from all participants according to the protocol ap-
proved by the Institutional Review Board for EwhaWomans
University, Mokdong Hospital (ECT 11-58-37).
DNA preparation and prescreening for CMT genes
DNA was purified from blood using a QIAamp blood
DNA purification kit (Qiagen, Hilden, Germany). Patient
samples were prescreened for 17p12 duplication, which
is a major genetic cause of demyelinating CMT, by using
hexaplex microsatellite PCR [21]. Sequencing was also
determined for the coding exons of major CMT-relevant
genes, including MPZ, PMP22, GJB1, and MFN2.
Exome sequencing and identification of causative mutations
Exome sequencing was performed for the proband of
FC307 family according to Lee et al. [22]. Functionally
significant variants (missense, nonsense, exonicindel and
splicing site variants) were first selected from WES
data, and then novel or uncommon variants (MAF ≤0.01)
registered in the dbSNP137 [23] and 1000 Genomes
database [24] were chosen. Homozygous or compound
heterozygous mutations were finally selected. Candi-
date variants were confirmed by Sanger’s sequencing
method using an ABI3130XL automatic genetic analyzer
(Applied Biosystems, Foster City, CA). The underlying
cause was determined by the presence of mutation only inthe patient within the family and the absence in 300
controls. Conservation analysis of protein sequences was
performed using MEGA5 version 5.05 software [25].
Clinical and electrophysiological assessments
The proband (Figure 1A, III-1), her parents (Figure 1A, II-3,
and −7), and grandparents (Figure 1A, I-1, -2, -3, and −4)
were examined for motor and sensory impairments, deep
tendon reflexes, and muscle atrophy. The strength of flexor
and extensor muscles was assessed manually using the
medical research council (MRC) scale. Physical disabilities
were assessed using a CMT neuropathy score (CMTNS)
[26]. Sensory impairments were assessed in terms of the
level and severity of pain, temperature, vibration, and
position. Age at onset was determined by asking patients
for the age when symptoms, i.e., distal muscle weakness,
foot deformity, or sensory change, first appeared.
Nerve conduction studies were performed with a surface
electrode. Motor nerve conduction velocities (MNCVs) of
the median and ulnar nerves were determined by providing
stimulation at the elbow and wrist while recording com-
pound muscle action potentials (CMAPs) over the abductor
pollicis brevis and adductor digiti quinti, respectively. In the
same manner, the MNCVs and CMAPs of the peroneal
and tibial nerves were determined. Sensory nerve conduc-
tion velocities (SNCVs) and action potentials (SNAPs) were
obtained from the median, ulnar, and sural nerves. Needle
electromyography (EMG) was performed for bilateral prox-
imal and distal limb muscles. The patient and her parents
underwent tests for visually evoked potentials and brain-
stem auditory evoked potentials.
MRIs of the brain, hip, thigh and lower leg
The proband was studied by examining MRIs of the
brain, hip, thigh, and lower leg, using a 1.5-T system















KIF1B NM_015074 c.2192A > G p.N731S 155 56 31 rs117525287/0.01 0.042
FIG 4 NM_014845 c.1090A > T p.M364L 177 191 87 rs2295837/0.10 0.268
c.1961T > C p.V654A 225 128 63 rs9885672/0.37 0.377
GARS NM_002047 c.124C > G p.P42A 51 14 8 rs1049402/0.67 0.380
ARHGEF10 NM_014629 c.824G > A p.R275H 225 124 58 rs145821459/<0.01 0.024
NEFL NM_006158 c.1413delC p.P471fs 105 115 106 rs11300136/– 0.697
IKBKAP NM_003640 c.3473C > T p.P1158L 108 103 44 rs1538660/0.22 0.301
c.3214T > A p.C1072S 225 67 30 rs3204145/0.22 0.310
c.2490A > G p.I830M 135 130 70 rs2230794/0.08 0.151
c.2446A > C p.I816L 82 171 154 rs2230793/0.29 0.310
c.2294G > A p.G765E 91 77 72 rs2230792/0.28 0.310
LRSAM1 NM_138361 c.952A > G p.N318D 157 40 19 rs1539567/0.74 0.690
SETX NM_015046 c.7834A > G p.S2612G 151 47 22 rs3739927/0.16 0.403
c.7759A > G p.I2587V 225 41 19 rs1056899/0.51 0.781
c.5563A > G p.T1855A 95 70 40 rs2296871/0.41 0.747
c.4156A > G p.I1386V 225 113 44 rs543573/0.59 0.273
c.3576T > G p.D1192E 225 71 25 rs1185193/0.66 0.293
c.1979C > G p.A660G 102 50 23 rs882709/0.21 0.387
IGHMBP2 NM_002180 c.602T > C p.L201S 156 83 78 rs560096/0.70 0.566
c.2636C > A p.T879K 166 37 29 rs17612126/0.23 0.355
c.2782G > A p.E928K 132 16 14 rs2275996/0.03 0.106
MTMR2 NM_016156 c.8A > C p.K3T 65 12 6 rs3824874/0.28 0.284
WNK1 NM_213655 c.3922A > C p.T1308P 33 42 13 rs956868/0.85 0.051
c.5273G > C p.C1758S 222 55 53 rs7955371/0.99 1.000
c.6180G > T p.M2060I 162 123 55 rs12828016/0.39 0.299
SEPT9 NM_006640 c.1672A > G p.M558V 222 13 13 rs2627223/0.92 0.937
PRX NM_181882 c.3394G > A p.G1132R 115 26 24 rs268674/0.96 1.000
ATP7A NM_000052 c.4048G > A p.E1350K 222 201 182 rs4826245/1.00 1.000
a GenBank registration number of reference sequence.
b cDNA numbering was achieved with +1, corresponding to the A of the ATG initiation codon.
c GenBank registration no./allele frequencies in the 1000 Genomes database (−: unreported).
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obtained in axial [field of view (FOV) 24–32 cm, slice
thickness 6 mm, and slice gap 0.5–1.0 mm] and coronal
planes (FOV 38–40 cm, slice thickness 4–5 mm, slice
gap 0.5–1.0 mm). The following protocol was used:
T1-weighted spin-echo (SE) (TR/TE 570–650/14–20,
512 matrices), T2-weighted SE (TR/TE 2800–4000/
96–99, 512 matrices), and fat-suppressed T2-weighted
SE (TR/TE 3090–4900/85–99, 512 matrices).
Histopathological examination
The distal sural nerve of patient (III-1) was biopsied at 19
years of age. The density of myelinated fibers (MFs), axonal
diameter, and myelin thickness were determined fromthe semi-thin transverse sections using a computer-
assisted image analyzer (AnalySIS; Soft Imaging System,
Münster, Germany). Ultrathin cut samples (60–65 nm)
were contrasted with uranyl acetate and lead citrate for
electron microscopy (H-7650, Hitachi, Japan). An immuno-
histochemical study was performed with anti-PLEKHG5
antibody (N-15: sc-130100, 1:50 dilution, Santa Cruz
Biotech, Santa Cruz, CA) and the findings were compared
with a control case (female, 39 years old).
Cloning, expression and reporter assay for PLEKHG5
PLEKHG5 (BC015231), which is fused with a c-myc epitope,
was obtained from Capital Biosciences (Rockville, MD).
Site-directed mutagenesis was performed to generate
Table 3 Clinical manifestations of patients with PLEKHG5 mutations
Disease Charcot-Marie-Tooth disease Lower motor neuron disease
Phenotype Motor and sensory neuropathy Motor neuropathy
Origin Korean (Asian) Mali (African)
Mutation Compound heterozygous missense Homozygous missense
Nucleotide change c.1988C > T, c.2458G > C c.1940T > C
Amino acid change p.Thr663Met, p.Gly820Arg p.Phe647Ser
Age at onset 8 years 2–11.5 years
Symptom at onset Distal muscle weakness of lower limbs Proximal muscle weakness and early
involvements of foot and hand
Muscle weakness
Upper limb, proximal No Yes
Upper limb, distal Yes Yes
Lower limb, proximal Yes Yes
Lower limb, distal Yes Yes
Muscle atrophy Proximal < distal Proximal = distal (generalized)
Sensory loss Yes No
Areflexia Yes Yes
Pyramidal sign No No
Bulbar symptom No No
Cranial neuropathy No No
Foot deformity Yes Yes
Scoliosis Yes Yes
Respiratory dysfunction No Yes (60%)
Wheelchair bound No Yes (80%)
Nerve conduction study Sensorimotor neuropathy Motor neuropathy
Electromyography Muscle denervation Muscle denervation
Sural nerve biopsy Severe loss of myelinated fibers
(297/mm2, normal: 9,800/mm2)
Normal
References This study Maystadt et al. (2006) [1]
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using a QuickChange Site-directed mutagenesis kit
(Stratagene, La Jolla, CA). DNA transfections into HEK293
cells were performed using each DNA and Lipofectamine
2000 (Invitrogen, Carlsbad, CA). Protein expression was
analyzed by immunocytochemistry using anti-Myc anti-
body (Abcam, Cambridge, UK) after transfection of each
vector. Reporter assay for NF-κB was achieved using a
reporter vector, pNF-κB-Luc-reporter (from Dr. Kim HT,
Sungkyunkwan University, Korea), and a luciferase assay
system (Promega, Madison, WI).
Results
Identification of compound heterozygous mutations in
PLEKHG5
To identify the disease-associated genetic defect of our
patient, we performed exome sequencing of the affected
individual (Table 1). We identified novel compound heterozy-
gous mutations, c.1988C > T (p.Thr663Met, paternal origin)and c.2458G > C (p.Gly820Arg, maternal origin) in the
PLEKHG5 gene in a Korean CMT family (family ID: FC307)
(Figure 1A and 1B). The mutations of her parents were
inherited from their mothers, respectively (Figure 1A).
Neither mutation has been reported in dbSNP137 or the
1000 Genomes database. In the 300 Korean controls,
the p.Thr663Met mutation was not found, while the
p.Gly820Arg was found in three control samples. Both
mutation sites were well conserved across species
(Figure 1C). In silico analysis using PolyPhen 2 soft-
ware [27] predicted that both mutations may affect
protein function with scores of 0.993 (p.Thr663Met)
and 1.000 (p.Gly820Arg). In addition to the compound
heterozygous mutations in PLEKHG5, several other
variants were identified in the more than 50 CMT-
associated genes (Table 2). However, no variant was
considered to be causative, because all the variants
were polymorphic; moreover, they did not fit the recessive
inheritance characteristic.
Table 4 Electrophysiological studies in the patient (III-1)
with a novel compound mutations in the PLEKHG5 gene
Items Determined values Normal value
Age at exam (years) 14 15 16 19
Side Right Right Right Right
Median nerve
TL (ms) 6.1 5.4 5.5 7.0 <3.9
CMAP (mV) 8.2 9.5 9.6 6.4 >6.0
MNCV(m/S) 25.3 24.7 25.6 29.3 >50.5
Ulnar nerve
TL (ms) 4.9 4.9 4.9 5.7 <3.0
CMAP (mV) 9.7 10.2 10.0 10.0 >8.0
MNCV(m/S) 25.0 22.4 20.4 25.0 >51.1
Peroneal nerve
TL (ms) A A A A <5.3
CMAP (mV) A A A A >1.6
MNCV(m/S) A A A A >41.2
Tibial nerve
TL (ms) 7.2 6.0 7.4 A <5.4
CMAP (mV) 0.6 0.3 0.2 A >6.0
MNCV(m/S) 19.2 15.8 13.4 A >41.1
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The clinical manifestations of the present patient and
the previously described patients with PLEKHG5 mutations
are shown in Table 3. The proband, a 19-year-old woman,
was the first child of healthy nonconsanguineous Korean
parents. On neurological examination and after electro-
physiological studies, the parents did not show any ab-
normalities. The proband was born at full term and the
perinatal history was unremarkable. Early motor milestones
were not delayed, and one year after her birth, she was able
to walk. At age 8 years, she experienced frequent falling and
noticed muscle weakness of the distal lower limbs. She
started to walk with short leg braces at 16 years of age.
Neurological examination at 19 years of age revealed muscle
weakness and atrophy of bilateral distal muscles, predomin-
antly at lower limbs rather than upper limbs. Bilateral pes
cavus, steppage gait, and atrophic changes of intrinsic foot
and calf muscles were noted, but scoliosis was not observed.
Sensitivity to pinprick, touch, position, and vibration de-
creased. Vibration and position senses were more severely
disturbed than pain and touch senses. Knee and ankle jerks
were absent. No pyramidal or cerebellar signs were detected.
CMTNS was 15. Elevated serum creatine kinase levels were
revealed (246 μmol/L, reference value: <185 μmol/L).Median sensory nerve
SNAP (μV) 6.5 4.8 7.8 8.0 >8.8
SNCV (m/s) 27.0 25.9 27.3 25.6 >39.3
Ulnar sensory nerve
SNAP (μV) 7.4 6.9 5.0 4.5 >7.9
SNCV (m/s) 23.4 21.9 22.3 23.7 >37.5
Sural nerve
SNAP (μV) A A A A >6.0
SNCV (m/s) A A A A >32.1
Bold character indicates abnormal values. A, absent potentials; TL, terminal
latency; CMAP, compound muscle action potential; MNCV, motor nerve
conduction velocity; SNAP, sensory nerve action potential; SNCV, sensory
nerve conduction velocity.Sensory and motor neuropathies
Data from the nerve conduction study are summarized in
Table 4. Median MNCVs ranged from 24.7 m/s to 29.3 m/s.
The results also revealed prolonged motor latencies, and no
motor responses were elicited by stimulation of peroneal
and tibial nerves at 19 years of age. SNAPs on bilateral
sural nerves were absent on all electrophysiological studies
(at 14, 15, 16 and 19 years old). In the upper limb, SNCVs
and SNAPs were decreased on bilateral median and
ulnar nerves. Needle EMG showed a neurogenic pattern
of muscle degeneration. Visually evoked potentials and
brainstem auditory-evoked potentials were normal.Fatty replacement of lower limb muscles
Brain and hip MRIs were normal. However, thigh and
lower leg MRIs of the patient demonstrated hyperintense
signal abnormalities. T1-weighted images showed severe
muscle atrophy and fatty replacement in the lower leg
muscles compared with the thigh, which is compatible
with a hypothesis of length-dependent axonal degeneration
(Figure 2A and 2B). At the thigh level, fatty replacement of
the vastus lateralis and semimembranous muscles was
observed, but more muscle remained than fat. Sartorius,
gracilis, biceps femoris, and rectus femoris muscles
contained some fatty streaks (Figure 2C). We could observe
a distinct pattern of muscle involvement; lower leg MRI
showed selective and predominant involvement of anterior
and lateral compartment muscles; however, superficialand deep posterior compartment muscles revealed mild
manifestations (Figure 2D and 2E).
Histopathological findings
Semi-thin transverse sections showed loss of large- and
medium-sized MFs, with small MFs remaining (Figure 3A).
The number of MFs was reduced (297/mm2) compared
with a control (20-year-old female, 9,800/mm2) (Figure 3B).
The range (1.2-4.6 μm) and average (2.4 μm) MF diameter
were also reduced compared with the control (2–12.5 μm
and 4.5 μm, respectively). The distribution pattern of MF
diameter was unimodal and composed of 75% of <3 μm
MFs. In addition, MF% area and g-ratio (axonal diameter/
MF diameter) were also reduced. The MF% area in this
Figure 2 T1-weighted MRI of the proband (III-1). (A, B) Coronal images of thigh (A) and lower leg (B). T1-weighted coronal leg MRIs of lower
extremities demonstrated more severe fatty replacement and muscle atrophies in the lower leg than did those of the thigh. (C) Axial image of
the middle thigh. Vastus lateralis, semimembranous muscles showed moderate to severe fatty replacements, but they revealed more muscles
than fat. However, sartorius, gracilis, biceps femoris, and rectus femoris muscles revealed fatty streaks. (D, E) Axial images at the upper third (D)
and lower third calf (E). T1-weighted images revealed predominantly severe involvement of anterior (black arrowhead; anterior tibialis, extensor
hallucis longus and digitorum longus) and lateral (white arrowhead; peroneus longus and brevis) compartment muscles, and superficial and deep
posterior compartment (arrow; soleus and tibialis posterior) muscles showed mild involvement.
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female: 25.2%). The range and average of g-ratio
(axonal diameter/MF diameter) were 0.38-0.73 and
0.56 ± 0.09, respectively (mean g-ratio at age 21–50 years
old: 0.66). The g-ratio >0.7 (abnormally thin myelin sheath)
consisted of 10% of MFs and g-ratio <0.4 (abnormally thick
myelin sheath) consisted of 1.7%. Electron microscopic
examination revealed that the remaining small MFs
showed occasional focal folding of myelin with very rare
evidence of regeneration (clusters of regenerating fibers)
(Figure 3C and 3D). The unmyelinated axons showed
suggestive clustering (reinnervated Büngner bands with
unmyelinated fibers) and atrophy. Endoneurial fibroblast
proliferation and large amounts of collagen deposition
were well documented.
Expression of mutant proteins
The immunohistochemical study with anti-PLEKHG5
antibody showed a focal positive reaction in Schwann
cell nuclei in this patient (Figure 3E) compared with a
diffuse positive reaction in axons and Schwann cell nuclei
in the control case (Figure 3F). To further investigate the
impact of the mutant proteins in cellular function andlocalization, we generated mutants using a BC015231
clone as a template. Cellular localization of the proteins
was analyzed after transfection of the genes into HEK293
cells. Overall, the proteins were localized in the cytoplasm
and there was no distinctive aggregation of any of the
three proteins (Figure 4).
The proteins were examined for ability to activate the
NF-κB pathway using a luciferase assay. Transfection of
wild-type PLEKHG5 significantly induced luciferase ac-
tivity. However, elevated levels of the activity were reduced
in mutant protein-expressing cells (Figure 5).
Discussion
We have identified a pair of novel compound heterozygous
mutations of PLEKHG5 as the underlying cause of the
disease in the CMT family with autosomal recessive
inheritance. Although the sample size in this family was
small, the mutations were in good agreement with affected
or carrier members in the pedigree. These identified
mutations have not been reported at either the CMT
or LMND mutation database or in related papers. We
believe that the identified PLEKHG5 mutations are respon-
sible for the CMT for the following reasons: (1) the patient
Figure 3 Histopathological findings of the distal sural nerve of the patient. (A) Toluidine blue-stained semi-thin transverse section
revealed loss of large MFs and remaining medium- and small-sized MFs with rarely noted regenerating axonal clusters and unmyelinated axons
with suggestive clustering and atrophy. (B) Histogram showing unimodal distribution pattern of myelinated fibers. (C and D) Electron
micrographs showed axonal atrophy, rare axonal clustering, occasional focal folding of myelin, and increased collagen deposition in the
endoneurium. (E) Immunohistochemical study with anti-PLEKHG5 antibody showed a focal positive reaction in the patient’s Schwann cell
nuclei. (F) Comparison with diffuse strong positive reaction in axons and Schwann cell nuclei in the control case (original magnification:
A, ×400; C, ×3000, D, ×8000, E and F, ×400).
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mutations, but no other family members or controls had
both heterozygous mutations simultaneously, (2) amino
acids at the mutation sites among different species are
well conserved, and (3) exome sequencing revealed that
no causative mutation of the many known CMT genes
was found in the present family.
Sensory neuropathy is a useful discriminating factor
between CMT and LMND [1,13]. LMND is characterized
by motor nerve degeneration in the anterior horn cell of the
spinal cord or the brainstem, and the diagnosis is confirmed
by the evidence of muscle degeneration with abnormal
motor conduction velocities without sensory neuropathy
[1,3]. However, CMT involves not only motor, but alsosensory neuropathies. The present patient showed clinical,
electrophysiological, and pathological evidence of sen-
sory nerve involvement; therefore, she was diagnosed
as having CMT.
It is interesting that the symptoms and signs of this
patient such as sensory loss and slow nerve conduc-
tion velocities suggested the possibility of demyelinat-
ing neuropathy; however, the distal sural nerve biopsy
revealed similarities with axonal neuropathy harboring
absence of medium- and large-sized MFs. Absence of
large MFs could explain the slow nerve conduction veloci-
ties and action potentials in this patient. The intermediate
form of CMT has been observed in cases with median
MNCVs between 25 and 45 m/s, and in our patient,
Figure 4 Cellular localization of wild-type and mutant PLEKHG5 proteins. Immunocytochemical analysis reveals that wild-type and mutant
PLEKHG5 proteins were localized in the cytoplasm and there was no distinctive aggregation of any of the proteins. HEK293 cells transfected with
wild-type or mutant PLEKHG5-expressing vectors were stained with DAPI (nucleus) and c-Myc antibody.
Kim et al. Orphanet Journal of Rare Diseases 2013, 8:104 Page 9 of 11
http://www.ojrd.com/content/8/1/104median MNCVs were at the lower extreme of the range
[16-18,28]. By neurophysiological and neuropathological
criteria, the current case was consistent with the RI-CMT.
Currently, information on the molecular function and
disease-associated mechanism of PLEKHG5 is limited: only
one homozygous mutation, p.F647S, was reported as aFigure 5 Activities of wild-type and mutant PLEKHG5. Compared
with wild-type, mutant PLEKHG5 proteins have defect in the activation of
NF-κB pathway. Luciferase activity measured in HEK293 cells, which were
treated with pNF-κB-Luc-reporter and PLEKHG5-expressing vectors.
Statistical significance was calculated using Student’s t test: *, p < .05.causative for autosomal recessive LMND. The site locates
within the PH domain and the mutation was suggested to
deteriorate the function on activation of NF-κB signaling
pathway. Thr663 lies within the PH domain as does the pre-
viously reported Phe647, while Gly820 does not belong to
any specific domain. Our in vitro data also suggest that these
patients might have a defect in activation of the NF-κB
signaling pathway. According to immunohistochemical
data from the patient and immunocytochemical study
using cloned mutants, the expression levels of the mutant
proteins are lower than that of wild-type protein. By
contrast with the p.F647S mutation, however, there was no
indication of intracellular aggregation of current mutants.
Therefore, these data imply that the low level of expression
and NF-κB activation might induce peripheral neuropathy
in the patient.
The PH domain of GEFs for Rho-related GTPase
plays a critical role in the spatial organization of major
signaling pathways, through their interaction with lipids
(especially with phosphoinositides) and proteins [29].
NF-κB signaling could be included in those pathways in
conjunction with the function of RhoA in triggering
the translocation of NF-κB into the nucleus, because
PLEKHG5 is known as an activator of RhoA exchange
factor. As well as its well-known function in immune
and inflammatory responses, the NF-κB signaling pathway
is also involved in the development and activity of the ner-
vous system. Particularly in the peripheral nervous system,
NF-κB stimulation has been shown to have essential roles
in the differentiation and myelinating programs as well as
Schwann cell regeneration [30]. However, several questions
Kim et al. Orphanet Journal of Rare Diseases 2013, 8:104 Page 10 of 11
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remain to be answeredabout the PH domain defect of
the PLEKHG5 protein and congenital dysfunction in
peripheral nervous system via NF-κB signaling pathway.
Other human neurodegenerative disease-related genes
sharing a PH/RhoGEF domain, such as DNM2, SBF2,
and ALS2, could provide important clues for these elusive
questions [31-33].
Conclusions
We identified novel compound heterozygous PLEKHG5
mutations as the underlying cause of RI-CMT. In the
present case, nerve conduction studies showed slow motor
and sensory nerve conduction, and the distal sural nerve
revealed marked loss of myelinated fibers. Our findings
significantly expand the phenotype of PLEKHG5 mutation;
therefore, genetic screening of PLEKHG5 should be consid-
ered in not only LMND but also RI-CMT families. We sug-
gest that PLEKHG5 plays an important role in both the
peripheral motor and sensory nervous systems.
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